

# Daniel Martins-de-Souza

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8902235/publications.pdf>

Version: 2024-02-01

205  
papers

6,014  
citations

87888

38  
h-index

102487

66  
g-index

231  
all docs

231  
docs citations

231  
times ranked

8844  
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-Cell RNA Sequencing and Its Applications in the Study of Psychiatric Disorders. Biological Psychiatry Global Open Science, 2023, 3, 329-339.	2.2	5
2	14-3-3 proteins at the crossroads of neurodevelopment and schizophrenia. World Journal of Biological Psychiatry, 2022, 23, 14-32.	2.6	4
3	BrJAC pays tribute to Prof. Dr. Jos�� Camillo Novello, a pioneer researcher in proteomics in Brazil and a gentle advisor. Brazilian Journal of Analytical Chemistry, 2022, 9, .	0.5	0
4	Cannabinoids modulate proliferation, differentiation, and migration signaling pathways in oligodendrocytes. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 1311-1323.	3.2	2
5	Nootropic effects of LSD: Behavioral, molecular and computational evidence. Experimental Neurology, 2022, 356, 114148.	4.1	11
6	Zika Virus Strains and Dengue Virus Induce Distinct Proteomic Changes in Neural Stem Cells and Neurospheres. Molecular Neurobiology, 2022, 59, 5549-5563.	4.0	2
7	An overview of the human brain myelin proteome and differences associated with schizophrenia. World Journal of Biological Psychiatry, 2021, 22, 271-287.	2.6	8
8	Transcriptome of iPSC-derived neuronal cells reveals a module of co-expressed genes consistently associated with autism spectrum disorder. Molecular Psychiatry, 2021, 26, 1589-1605.	7.9	44
9	Microbiota-derived short-chain fatty acids do not interfere with SARS-CoV-2 infection of human colonic samples. Gut Microbes, 2021, 13, 1-9.	9.8	38
10	DIA-MSE to Study Microglial Function in. Methods in Molecular Biology, 2021, 2228, 341-352.	0.9	0
11	Proteomics for Target Identification in Psychiatric and Neurodegenerative Disorders. Advances in Experimental Medicine and Biology, 2021, 1286, 251-264.	1.6	3
12	Human Blood Plasma Investigation Employing 2D UPLC-UDMSE Data-Independent Acquisition Proteomics. Methods in Molecular Biology, 2021, 2259, 153-165.	0.9	1
13	Addendum: Cruz, B., et al. Leucine-Rich Diet Modulates the Metabolomic and Proteomic Profile of Skeletal Muscle during Cancer Cachexia. Cancers 2020, 12, 1880. Cancers, 2021, 13, 880.	3.7	0
14	Linking proteomic alterations in schizophrenia hippocampus to NMDAr hypofunction in human neurons and oligodendrocytes. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 1579-1586.	3.2	5
15	Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Frontiers in Molecular Neuroscience, 2021, 14, 673144.	2.9	3
16	Molecular Mechanisms Associated with Antidepressant Treatment on Major Depression. Complex Psychiatry, 2021, 7, 49-59.	0.9	5
17	A glimpse on the architecture of hnRNP C1/C2 interaction network in cultured oligodendrocytes. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2021, 1869, 140711.	2.3	1
18	Biological Applications for LC-MS-Based Proteomics. Advances in Experimental Medicine and Biology, 2021, 1336, 17-29.	1.6	4

#	ARTICLE	IF	CITATIONS
19	Human disease biomarker panels through systems biology. <i>Biophysical Reviews</i> , 2021, 13, 1179-1190.	3.2	8
20	A proteomic signature associated to atypical antipsychotic response in schizophrenia patients: a pilot study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 127-134.	3.2	11
21	Leucine-Rich Diet Modulates the Metabolomic and Proteomic Profile of Skeletal Muscle during Cancer Cachexia. <i>Cancers</i> , 2020, 12, 1880.	3.7	17
22	Ovariectomy modifies lipid metabolism of retroperitoneal white fat in rats: a proteomic approach. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2020, 319, E427-E437.	3.5	9
23	Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1 $\alpha$ /Glycolysis-Dependent Axis. <i>Cell Metabolism</i> , 2020, 32, 437-446.e5.	16.2	578
24	Ubiquitinâ€“proteasome system, lipid metabolism and DNA damage repair are triggered by antipsychotic medication in human oligodendrocytes: implications in schizophrenia. <i>Scientific Reports</i> , 2020, 10, 12655.	3.3	14
25	Modulation of cognition and neuronal plasticity in gain- and loss-of-function mouse models of the schizophrenia risk gene Tcf4. <i>Translational Psychiatry</i> , 2020, 10, 343.	4.8	16
26	Evidence of macrophage modulation in the mouse pubic symphysis remodeling during the end of first pregnancy and postpartum. <i>Scientific Reports</i> , 2020, 10, 12403.	3.3	1
27	Digging deeper in the proteome of different regions from schizophrenia brains. <i>Journal of Proteomics</i> , 2020, 223, 103814.	2.4	17
28	Drug repositioning for psychiatric and neurological disorders through a network medicine approach. <i>Translational Psychiatry</i> , 2020, 10, 141.	4.8	24
29	Blood plasma proteomic modulation induced by olanzapine and risperidone in schizophrenia patients. <i>Journal of Proteomics</i> , 2020, 224, 103813.	2.4	8
30	Novel Treatment Strategies Targeting Myelin and Oligodendrocyte Dysfunction in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2020, 11, 379.	2.6	37
31	Changes in the blood plasma lipidome associated with effective or poor response to atypical antipsychotic treatments in schizophrenia patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 101, 109945.	4.8	18
32	Liquid Chromatography Tandem Mass Spectrometry Analysis of Proteins Associated with Age-Related Disorders in Human Pituitary Tissue. <i>Methods in Molecular Biology</i> , 2020, 2138, 263-276.	0.9	1
33	Proteomic Analysis of Rat Hippocampus for Studies of Cognition and Memory Loss with Aging. <i>Methods in Molecular Biology</i> , 2020, 2138, 407-417.	0.9	3
34	The state of the art of nanopsychiatry for schizophrenia diagnostics and treatment. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 28, 102222.	3.3	9
35	Mass spectrometry-based proteomics to understand schizophrenia. <i>Brazilian Journal of Analytical Chemistry</i> , 2020, 7, 13-17.	0.5	2
36	Human Cerebral Organoids and Fetal Brain Tissue Share Proteomic Similarities. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 303.	3.7	58

#	ARTICLE	IF	CITATIONS
37	Blood plasma high abundant protein depletion unintentionally carries over 100 proteins. Separation Science Plus, 2019, 2, 449-456.	0.6	4
38	Quantitative Subcellular Proteomics of the Orbitofrontal Cortex of Schizophrenia Patients. Journal of Proteome Research, 2019, 18, 4240-4253.	3.7	21
39	Biochemical Pathways Triggered by Antipsychotics in Human Oligodendrocytes: Potential of Discovering New Treatment Targets. Frontiers in Pharmacology, 2019, 10, 186.	3.5	12
40	Protein disulfide isomerase plasma levels in healthy humans reveal proteomic signatures involved in contrasting endothelial phenotypes. Redox Biology, 2019, 22, 101142.	9.0	17
41	Proteomic Markers for Depression. Advances in Experimental Medicine and Biology, 2019, 1118, 191-206.	1.6	11
42	Human leukemia cells (HL-60) proteomic and biological signatures underpinning cryo-damage are differentially modulated by novel cryo-additives. GigaScience, 2019, 8, .	6.4	6
43	Maturation of a Human Oligodendrocyte Cell Line. Methods in Molecular Biology, 2019, 1916, 113-121.	0.9	3
44	A Guide to Mass Spectrometry-Based Quantitative Proteomics. Methods in Molecular Biology, 2019, 1916, 3-39.	0.9	17
45	Using Co-immunoprecipitation and Shotgun Mass Spectrometry for Protein-Protein Interaction Identification in Cultured Human Oligodendrocytes. Neuromethods, 2019, , 37-47.	0.3	1
46	A Complete Proteomic Workflow to Study Brain-Related Disorders via Postmortem Tissue. Methods in Molecular Biology, 2019, 1916, 319-328.	0.9	7
47	Effects on Glial Cell Glycolysis in Schizophrenia: An Advanced Aging Phenotype?. Advances in Experimental Medicine and Biology, 2019, 1178, 25-38.	1.6	7
48	84. Cerebral Organoids-Derived Astrocytes to Understanding Schizophrenia. Biological Psychiatry, 2018, 83, S35.	1.3	0
49	Cannabinoids and glial cells: possible mechanism to understand schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 727-737.	3.2	13
50	2DE Gels: A Story of Love and Hate in Proteomics. Proteomics, 2018, 18, e1700472.	2.2	2
51	Blood plasma/IgG N-glycome biosignatures associated with major depressive disorder symptom severity and the antidepressant response. Scientific Reports, 2018, 8, 179.	3.3	30
52	Elemental fingerprinting of schizophrenia patient blood plasma before and after treatment with antipsychotics. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 565-570.	3.2	15
53	13.3 EFFECTS OF CANNABINOIDS ON A HUMAN OLIGODENDROCYTE CULTURE: IMPLICATIONS FOR SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S22-S22.	4.3	0
54	Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients. Frontiers in Psychiatry, 2018, 9, 209.	2.6	21

#	ARTICLE	IF	CITATIONS
55	Proteomics and Lipidomics in the Elucidation of Endocannabinoid Signaling in Healthy and Schizophrenia Brains. <i>Proteomics</i> , 2018, 18, e1700270.	2.2	6
56	Modeling Schizophrenia with Human Stem Cells. , 2018, , 13-26.		1
57	Peptidomic analysis of the anterior temporal lobe and corpus callosum from schizophrenia patients. <i>Journal of Proteomics</i> , 2017, 151, 97-105.	2.4	22
58	Unveiling alternative splice diversity from human oligodendrocyte proteome data. <i>Journal of Proteomics</i> , 2017, 151, 293-301.	2.4	12
59	Psychiatric disorders biochemical pathways unraveled by human brain proteomics. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 3-17.	3.2	35
60	Zika virus disrupts molecular fingerprinting of human neurospheres. <i>Scientific Reports</i> , 2017, 7, 40780.	3.3	120
61	DIA is not a new mass spectrometry acquisition method. <i>Proteomics</i> , 2017, 17, 1700017.	2.2	11
62	Two-Dimensional Gel Electrophoresis: A Reference Protocol. <i>Advances in Experimental Medicine and Biology</i> , 2017, 974, 175-182.	1.6	3
63	Application of Proteomic Techniques for Improved Stratification and Treatment of Schizophrenia Patients. <i>Advances in Experimental Medicine and Biology</i> , 2017, 974, 3-19.	1.6	7
64	A Selected Reaction Monitoring Mass Spectrometry Protocol for Validation of Proteomic Biomarker Candidates in Studies of Psychiatric Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2017, 974, 213-218.	1.6	0
65	The Application of Multiplex Biomarker Techniques for Improved Stratification and Treatment of Schizophrenia Patients. <i>Methods in Molecular Biology</i> , 2017, 1546, 19-35.	0.9	7
66	Identifying Biomarker Candidates in the Blood Plasma or Serum Proteome. <i>Advances in Experimental Medicine and Biology</i> , 2017, 974, 193-203.	1.6	12
67	Combining Patient-Reprogrammed Neural Cells and Proteomics as a Model to Study Psychiatric Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2017, 974, 279-287.	1.6	8
68	MK-801-Treated Oligodendrocytes as a Cellular Model to Study Schizophrenia. <i>Advances in Experimental Medicine and Biology</i> , 2017, 974, 269-277.	1.6	17
69	What Have Proteomic Studies Taught Us About Novel Drug Targets in Autism?. <i>Advances in Experimental Medicine and Biology</i> , 2017, 974, 49-67.	1.6	0
70	Derivation of Functional Human Astrocytes from Cerebral Organoids. <i>Scientific Reports</i> , 2017, 7, 45091.	3.3	75
71	Selective Reaction Monitoring Mass Spectrometry for Quantitation of Glycolytic Enzymes in Postmortem Brain Samples. <i>Advances in Experimental Medicine and Biology</i> , 2017, 974, 205-212.	1.6	1
72	Application of iTRAQ Shotgun Proteomics for Measurement of Brain Proteins in Studies of Psychiatric Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2017, 974, 219-227.	1.6	5

#	ARTICLE	IF	CITATIONS
73	Co-immunoprecipitation for Deciphering Protein Interactomes. <i>Advances in Experimental Medicine and Biology</i> , 2017, 974, 229-236.	1.6	8
74	Application of Proteomic Approaches to Accelerate Drug Development for Psychiatric Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2017, 974, 69-84.	1.6	1
75	LC-MSE for Qualitative and Quantitative Proteomic Studies of Psychiatric Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2017, 974, 115-129.	1.6	1
76	Characterization of a Protein Interactome by Co-Immunoprecipitation and Shotgun Mass Spectrometry. <i>Methods in Molecular Biology</i> , 2017, 1546, 223-234.	0.9	17
77	LC-MSE, Multiplex MS/MS, Ion Mobility, and Label-Free Quantitation in Clinical Proteomics. <i>Methods in Molecular Biology</i> , 2017, 1546, 57-73.	0.9	36
78	Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT. <i>Scientific Reports</i> , 2017, 7, 12863.	3.3	87
79	Synaptosomal Proteome of the Orbitofrontal Cortex from Schizophrenia Patients Using Quantitative Label-Free and iTRAQ-Based Shotgun Proteomics. <i>Journal of Proteome Research</i> , 2017, 16, 4481-4494.	3.7	44
80	Enabling point-of-care testing and personalized medicine for schizophrenia. <i>NPJ Schizophrenia</i> , 2017, 3, 1.	3.6	30
81	The Nuclear Proteome of White and Gray Matter from Schizophrenia Postmortem Brains. <i>Molecular Neuropsychiatry</i> , 2017, 3, 37-52.	2.9	32
82	Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 330-356.	2.6	33
83	The Energy Metabolism Dysfunction in Psychiatric Disorders Postmortem Brains: Focus on Proteomic Evidence. <i>Frontiers in Neuroscience</i> , 2017, 11, 493.	2.8	108
84	Proteomic Differences in Blood Plasma Associated with Antidepressant Treatment Response. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 272.	2.9	14
85	Ion Mobility-Enhanced Data-Independent Acquisitions Enable a Deep Proteomic Landscape of Oligodendrocytes. <i>Proteomics</i> , 2017, 17, 1700209.	2.2	15
86	Depletion of Highly Abundant Proteins of the Human Blood Plasma: Applications in Proteomics Studies of Psychiatric Disorders. <i>Methods in Molecular Biology</i> , 2017, 1546, 195-204.	0.9	11
87	Simultaneous Two-Dimensional Difference Gel Electrophoresis (2D-DIGE) Analysis of Two Distinct Proteomes. <i>Methods in Molecular Biology</i> , 2017, 1546, 205-212.	0.9	4
88	Comprehensive Shotgun Proteomic Analyses of Oligodendrocytes Using Ion Mobility and Data-Independent Acquisition. <i>Neuromethods</i> , 2017, , 65-74.	0.3	9
89	Making Sense of Blood-Based Proteomics and Metabolomics in Psychiatric Research. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv138.	2.1	35
90	Effect of MK-801 and Clozapine on the Proteome of Cultured Human Oligodendrocytes. <i>Frontiers in Cellular Neuroscience</i> , 2016, 10, 52.	3.7	35

#	ARTICLE	IF	CITATIONS
91	Human brain proteome in health and disease. <i>Proteomics - Clinical Applications</i> , 2016, 10, 1147-1147.	1.6	3
92	Differential proteome and phosphoproteome may impact cell signaling in the corpus callosum of schizophrenia patients. <i>Schizophrenia Research</i> , 2016, 177, 70-77.	2.0	22
93	Employing proteomics to unravel the molecular effects of antipsychotics and their role in schizophrenia. <i>Proteomics - Clinical Applications</i> , 2016, 10, 442-455.	1.6	13
94	Dunn's effect over Brazilian proteomics. <i>Proteomics</i> , 2016, 16, 2845-2846.	2.2	0
95	Proteomics and molecular tools for unveiling missing links in the biochemical understanding of schizophrenia. <i>Proteomics - Clinical Applications</i> , 2016, 10, 1148-1158.	1.6	14
96	Key players in neurodegenerative disorders in focus – New insights into the proteomic profile of Alzheimer's disease, schizophrenia, ALS, and multiple sclerosis – 24th HUPO BPP Workshop. <i>Proteomics</i> , 2016, 16, 1047-1050.	2.2	2
97	The emergence of point-of-care blood-based biomarker testing for psychiatric disorders: enabling personalized medicine. <i>Biomarkers in Medicine</i> , 2016, 10, 431-443.	1.4	26
98	Pioneering ambient mass spectrometry imaging in psychiatry: Potential for new insights into schizophrenia. <i>Schizophrenia Research</i> , 2016, 177, 67-69.	2.0	11
99	Brain Proteomics. <i>Proteomics - Clinical Applications</i> , 2015, 9, 795-795.	1.6	1
100	The proteome of schizophrenia. <i>NPJ Schizophrenia</i> , 2015, 1, 14003.	3.6	96
101	Biological pathways modulated by antipsychotics in the blood plasma of schizophrenia patients and their association to a clinical response. <i>NPJ Schizophrenia</i> , 2015, 1, 15050.	3.6	23
102	Disturbed macro-connectivity in schizophrenia linked to oligodendrocyte dysfunction: from structural findings to molecules. <i>NPJ Schizophrenia</i> , 2015, 1, 15034.	3.6	64
103	Deciphering the biochemistry and identifying biomarkers to multiple sclerosis. <i>Proteomics</i> , 2015, 15, 3281-3282.	2.2	0
104	The protein interactome of collapsin response mediator protein-2 (CRMP2/DPYSL2) reveals novel partner proteins in brain tissue. <i>Proteomics - Clinical Applications</i> , 2015, 9, 817-831.	1.6	37
105	MK-801 treatment affects glycolysis in oligodendrocytes more than in astrocytes and neuronal cells: insights for schizophrenia. <i>Frontiers in Cellular Neuroscience</i> , 2015, 09, 180.	3.7	35
106	Proteomics of the corpus callosum unravel pivotal players in the dysfunction of cell signaling, structure, and myelination in schizophrenia brains. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 601-612.	3.2	70
107	Clozapine promotes glycolysis and myelin lipid synthesis in cultured oligodendrocytes. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 384.	3.7	45
108	Proteomic changes in serum of first onset, antidepressant drug-naïve major depression patients. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 1599-1608.	2.1	91



#	ARTICLE	IF	CITATIONS
109	Plasma fibrinogen: now also an antidepressant response marker?. <i>Translational Psychiatry</i> , 2014, 4, e352-e352.	4.8	17
110	Proteomic Characterization of the Brain and Cerebrospinal Fluid of Schizophrenia Patients. <i>Advances in Biological Psychiatry</i> , 2014, , 1-1.	0.2	0
111	OLIGODENDROCYTE-TARGETED PROTEOMICS: INSIGHTS ABOUT SCHIZOPHRENIA. <i>Schizophrenia Research</i> , 2014, 153, S10.	2.0	0
112	Blood Mononuclear Cell Proteome Suggests Integrin and Ras Signaling as Critical Pathways for Antidepressant Treatment Response. <i>Biological Psychiatry</i> , 2014, 76, e15-e17.	1.3	22
113	2DE: The Phoenix of Proteomics. <i>Journal of Proteomics</i> , 2014, 104, 140-150.	2.4	123
114	S100B is downregulated in the nuclear proteome of schizophrenia corpus callosum. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2014, 264, 311-316.	3.2	18
115	The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles. <i>Proteomics</i> , 2014, 14, 1472-1479.	2.2	46
116	Ten years of proteomics in multiple sclerosis. <i>Proteomics</i> , 2014, 14, 467-480.	2.2	31
117	Deciphering the Human Brain Proteome: Characterization of the Anterior Temporal Lobe and Corpus Callosum As Part of the Chromosome 15-centric Human Proteome Project. <i>Journal of Proteome Research</i> , 2014, 13, 147-157.	3.7	16
118	Dysregulated Expression of Neuregulin-1 by Cortical Pyramidal Neurons Disrupts Synaptic Plasticity. <i>Cell Reports</i> , 2014, 8, 1130-1145.	6.4	81
119	Decrease of serum S100B during an oral glucose tolerance test correlates inversely with the insulin response. <i>Psychoneuroendocrinology</i> , 2014, 39, 33-38.	2.7	11
120	Brain Quantitative Proteomics Combining GeLC-MS and Isotope-Coded Protein Labeling (ICPL). <i>Methods in Molecular Biology</i> , 2014, 1156, 175-185.	0.9	12
121	Using Mass Spectrometry-Based Peptidomics to understand the Brain and Disorders such as Parkinson's Disease and Schizophrenia. <i>Current Topics in Medicinal Chemistry</i> , 2014, 14, 369-381.	2.1	10
122	Proteomics, metabolomics, and protein interactomics in the characterization of the molecular features of major depressive disorder. <i>Dialogues in Clinical Neuroscience</i> , 2014, 16, 63-73.	3.7	72
123	Identification of Protein Biomarkers in Human Serum Using iTRAQ and Shotgun Mass Spectrometry. <i>Methods in Molecular Biology</i> , 2013, 1061, 291-307.	0.9	5
124	Proteomic Similarities Between Heterozygous Reeler Mice and Schizophrenia. <i>Biological Psychiatry</i> , 2013, 74, e5-e10.	1.3	11
125	Is clinical proteomics heading towards to "bench to bedside"? <i>Translational Proteomics</i> , 2013, 1, 53-56.	1.2	5
126	Affinity Depletion of Plasma and Serum for Mass Spectrometry-Based Proteome Analysis. <i>Methods in Molecular Biology</i> , 2013, 1002, 1-11.	0.9	28



#	ARTICLE	IF	CITATIONS
127	Proteomic profiling in schizophrenia: enabling stratification for more effective treatment. <i>Genome Medicine</i> , 2013, 5, 25.	8.2	19
128	Proteome profiling of peripheral mononuclear cells from human blood. <i>Proteomics</i> , 2013, 13, 893-897.	2.2	16
129	The human oligodendrocyte proteome. <i>Proteomics</i> , 2013, 13, 3548-3553.	2.2	24
130	Biomarkers for Psychiatric Disorders: Where Are We Standing?. <i>Disease Markers</i> , 2013, 35, 1-2.	1.3	31
131	Testes sanguíneos de biomarcadores para diagnóstico e tratamento de desordens mentais: foco em esquizofrenia. <i>Revista De Psiquiatria Clinica</i> , 2013, 40, 02-09.	0.6	9
132	Os efeitos do estresse na função do eixo hipotálamo-pituitário-adrenal em indivíduos com esquizofrenia. <i>Revista De Psiquiatria Clinica</i> , 2013, 40, 20-27.	0.6	6
133	Análise proteômica da esquizofrenia. <i>Revista De Psiquiatria Clinica</i> , 2013, 40, 16-19.	0.6	0
134	Proteomic biomarkers for psychiatric disorders: a progress update. <i>Biomarkers in Medicine</i> , 2012, 6, 189-192.	1.4	5
135	Proteomics Tackling Schizophrenia as a Pathway Disorder. <i>Schizophrenia Bulletin</i> , 2012, 38, 1107-1108.	4.3	28
136	Comprehending depression through proteomics. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 1373-1374.	2.1	9
137	Analysis of the rat hypothalamus proteome by data-independent label-free <sc>LC</sc>-<sc>MS</sc>/<sc>MS</sc>. <i>Proteomics</i> , 2012, 12, 3386-3392.	2.2	11
138	Differential phosphorylation of serum proteins reflecting inflammatory changes in schizophrenia patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 453-455.	3.2	13
139	Phosphoproteomic differences in major depressive disorder postmortem brains indicate effects on synaptic function. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 657-666.	3.2	67
140	Post-translational modification of the RhoGTPase activating protein 21, ARHGAP21, by SUMO2/3. <i>FEBS Letters</i> , 2012, 586, 3522-3528.	2.8	10
141	Clinical use of phosphorylated proteins in blood serum analysed by immobilised metal ion affinity chromatography and mass spectrometry. <i>Journal of Proteomics</i> , 2012, 76, 36-42.	2.4	20
142	Protein phosphorylation patterns in serum from schizophrenia patients and healthy controls. <i>Journal of Proteomics</i> , 2012, 76, 43-55.	2.4	80
143	Identification of a blood-based biological signature in subjects with psychiatric disorders prior to clinical manifestation. <i>World Journal of Biological Psychiatry</i> , 2012, 13, 627-632.	2.6	50
144	Purification and inflammatory edema induced by two PLA2 (Anch TX-I and Anch TX-II) from sea anemone <i>Anthothoe chilensis</i> (Actiniaria: Sagartiidae). <i>Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology</i> , 2012, 161, 170-177.	1.6	7

#	ARTICLE	IF	CITATIONS
145	Proteome analysis of spinal cord during the clinical course of monophasic experimental autoimmune encephalomyelitis. <i>Proteomics</i> , 2012, 12, 2656-2662.	2.2	18
146	Brazil: The Country of Proteomics. <i>Proteomics</i> , 2012, 12, 2599-2600.	2.2	2
147	The application of selective reaction monitoring confirms dysregulation of glycolysis in a preclinical model of schizophrenia. <i>BMC Research Notes</i> , 2012, 5, 146.	1.4	31
148	Translational strategies to schizophrenia from a proteomic perspective. <i>Translational Neuroscience</i> , 2012, 3, .	1.4	3
149	Proteomic approaches to unravel the complexity of schizophrenia. <i>Expert Review of Proteomics</i> , 2012, 9, 97-108.	3.0	28
150	Proteomic Analysis Identifies Dysfunction in Cellular Transport, Energy, and Protein Metabolism in Different Brain Regions of Atypical Frontotemporal Lobar Degeneration. <i>Journal of Proteome Research</i> , 2012, 11, 2533-2543.	3.7	73
151	Characterization of the human primary visual cortex and cerebellum proteomes using shotgun mass spectrometryâ€dataâ€independent analyses. <i>Proteomics</i> , 2012, 12, 500-504.	2.2	15
152	To label or not to label: Applications of quantitative proteomics in neuroscience research. <i>Proteomics</i> , 2012, 12, 736-747.	2.2	60
153	Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. <i>Translational Psychiatry</i> , 2012, 2, e87-e87.	4.8	162
154	Increased stress reactivity is associated with reduced hippocampal activity and neuronal integrity along with changes in energy metabolism. <i>European Journal of Neuroscience</i> , 2012, 35, 412-422.	2.6	38
155	Functional and structural characterization of a new serine protease with thrombin-like activity TLBan from <i>Bothrops andianus</i> (Andean Lancehead) snake venom. <i>Toxicon</i> , 2012, 59, 231-240.	1.6	17
156	Differential expression of HINT1 in schizophrenia brain tissue. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 167-172.	3.2	24
157	Abnormalities in Metabolism and Hypothalamicâ€Pituitaryâ€Adrenal Axis Function in Schizophrenia. <i>International Review of Neurobiology</i> , 2011, 101, 145-168.	2.0	24
158	The Role of Energy Metabolism Dysfunction and Oxidative Stress in Schizophrenia Revealed by Proteomics. <i>Antioxidants and Redox Signaling</i> , 2011, 15, 2067-2079.	5.4	113
159	Proteomic Technologies for Biomarker Studies in Psychiatry. <i>International Review of Neurobiology</i> , 2011, 101, 65-94.	2.0	31
160	The need for phosphoproteomic approaches in psychiatric research. <i>Journal of Psychiatric Research</i> , 2011, 45, 1404-1406.	3.1	13
161	Proteome analyses of cultured astrocytes treated with MK-801 and clozapine: similarities with schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 217-228.	3.2	36
162	The Usage of Codons Which are Similar to Stop Codons in the Genomes of <i>Xylella fastidiosa</i> and <i>Xanthomonas citri</i> . <i>Current Microbiology</i> , 2011, 62, 1090-1095.	2.2	1

#	ARTICLE	IF	CITATIONS
163	Quantitative proteomics for investigating psychiatric disorders. <i>Proteomics - Clinical Applications</i> , 2011, 5, 38-49.	1.6	57
164	Proteomic changes induced by anaesthesia and muscle relaxant treatment prior to electroconvulsive therapy. <i>Proteomics - Clinical Applications</i> , 2011, 5, 644-649.	1.6	18
165	Characterizing the proteome of the human dorsolateral prefrontal cortex by shotgun mass spectrometry. <i>Proteomics</i> , 2011, 11, 2347-2353.	2.2	22
166	Characterization of the human serum depletome by label-free shotgun proteomics. <i>Journal of Separation Science</i> , 2011, 34, 1621-1626.	2.5	36
167	Biochemical and pharmacological characterization of PhTX-I a new myotoxic phospholipase A2 isolated from Porthidium hyoprora snake venom. <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2011, 154, 108-119.	2.6	19
168	Proteomics as a Tool for Understanding Schizophrenia. <i>Clinical Psychopharmacology and Neuroscience</i> , 2011, 9, 95-101.	2.0	22
169	What Does Proteomics Tell Us About Schizophrenia?. , 2011, , 345-366.		1
170	The role of proteomics in depression research. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010, 260, 499-506.	3.2	54
171	Is the word "biomarker"™ being properly used by proteomics research in neuroscience?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010, 260, 561-562.	3.2	36
172	Proteome analysis of lumbar spinal cord from rats submitted to peripheral lesion during neonatal period. <i>Journal of Neural Transmission</i> , 2010, 117, 689-693.	2.8	1
173	Shotgun Mass Spectrometry Workflow Combining IEF and LC-MALDI-TOF/TOF. <i>Protein Journal</i> , 2010, 29, 99-102.	1.6	27
174	Neurotoxic, Myotoxic and Cytolytic Activities of the New Basic PLA2 Isoforms BmjeTX-I and BmjeTX-II Isolated from the Bothrops marajoensis (Marajó³ Lancehead) Snake Venom. <i>Protein Journal</i> , 2010, 29, 103-113.	1.6	21
175	Purification and Characterization of a New Weak Hemorrhagic Metalloproteinase BmHF-1 from Bothrops marajoensis Snake Venom. <i>Protein Journal</i> , 2010, 29, 407-416.	1.6	15
176	Proteome and transcriptome analysis suggests oligodendrocyte dysfunction in schizophrenia. <i>Journal of Psychiatric Research</i> , 2010, 44, 149-156.	3.1	75
177	Sex-specific proteome differences in the anterior cingulate cortex of schizophrenia. <i>Journal of Psychiatric Research</i> , 2010, 44, 989-991.	3.1	72
178	Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. <i>Journal of Psychiatric Research</i> , 2010, 44, 1176-1189.	3.1	158
179	Biological and biochemical characterization of two new PLA2 isoforms Cdc-9 and Cdc-10 from Crotalus durissus cumanensis snake venom. <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2010, 151, 66-74.	2.6	19
180	Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 719-728.	2.6	47

#	ARTICLE	IF	CITATIONS
181	Structural and pharmacological characterization of the crotoamine isoforms III-4 (MYX4_CROCu) and III-7 (MYX7_CROCu) isolated from the <i>Crotalus durissus cumanensis</i> venom. <i>Toxicon</i> , 2010, 55, 1443-1452.	1.6	17
182	Isolation and functional characterization of a new acidic PLA2 Ba SpII RP4 of the <i>Bothrops alternatus</i> snake venom from Argentina. <i>Toxicon</i> , 2010, 56, 64-74.	1.6	40
183	Proteome analysis of schizophrenia brain tissue. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 110-120.	2.6	82
184	Genetic and Proteomic Studies in Schizophrenia. , 2010, , 193-218.		0
185	Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. <i>Journal of Psychiatric Research</i> , 2009, 43, 978-986.	3.1	165
186	Shotgun mass spectrometry analysis of the human thalamus proteome. <i>Journal of Separation Science</i> , 2009, 32, 1231-1236.	2.5	21
187	Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. <i>Journal of Neural Transmission</i> , 2009, 116, 275-289.	2.8	137
188	Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 151-163.	3.2	180
189	Proteomics is not only a biomarker discovery tool. <i>Proteomics - Clinical Applications</i> , 2009, 3, 1136-1139.	1.6	7
190	Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. <i>BMC Psychiatry</i> , 2009, 9, 17.	2.6	133
191	Structural and functional characterization of brazilitoxins II and III (BbTX-II and -III), two myotoxins from the venom of <i>Bothrops brazili</i> snake. <i>Toxicon</i> , 2009, 54, 818-827.	1.6	20
192	Toluene gas phase biofiltration by <i>Paecilomyces lilacinus</i> and isolation and identification of a hydrophobin protein produced thereof. <i>Applied Microbiology and Biotechnology</i> , 2008, 80, 147-54.	3.6	39
193	Proteome analysis of human dorsolateral prefrontal cortex using shotgun mass spectrometry. <i>Journal of Separation Science</i> , 2008, 31, 3122-3126.	2.5	13
194	Structural and functional characterization of myotoxin, Cr-IV 1, a phospholipase A2 D49 from the venom of the snake <i>Calloselasma rhodostoma</i> . <i>Biologicals</i> , 2008, 36, 168-176.	1.4	14
195	Characterization of the C-terminal half of human juvenile myoclonic epilepsy protein EFHC1: Dimer formation blocks Ca <sup>2+</sup> and Mg <sup>2+</sup> binding to its functional EF-hand. <i>Archives of Biochemistry and Biophysics</i> , 2008, 477, 131-138.	3.0	6
196	The untiring search for the most complete proteome representation: reviewing the methods. <i>Briefings in Functional Genomics &amp; Proteomics</i> , 2008, 7, 312-321.	3.8	18
197	RNA Biomarkers in Schizophrenia. , 2008, , 97-127.		1
198	<i>Xylella fastidiosa</i> disturbs nitrogen metabolism and causes a stress response in sweet orange <i>Citrus sinensis</i> cv. Pera. <i>Journal of Experimental Botany</i> , 2007, 58, 2733-2744.	4.8	17

#	ARTICLE	IF	CITATIONS
199	The use of ASB-14 in combination with CHAPS is the best for solubilization of human brain proteins for two-dimensional gel electrophoresis. Briefings in Functional Genomics & Proteomics, 2007, 6, 70-75.	3.8	46
200	Absence of Classical Heat Shock Response in the Citrus Pathogen <i>Xylella fastidiosa</i> . Current Microbiology, 2007, 54, 119-123.	2.2	6
201	Structural and Biological Characterization of Two Crotamine Isoforms IV-2 and IV-3 Isolated from the <i>Crotalus durissus cumanensis</i> Venom. Protein Journal, 2007, 26, 533-540.	1.6	15
202	Comparative analysis of two-dimensional electrophoresis maps (2-DE) of <i>Helicobacter pylori</i> from Brazilian patients with chronic gastritis and duodenal ulcer: a preliminary report. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2006, 48, 175-177.	1.1	8
203	Proteome analysis of the plant pathogen <i>Xylella fastidiosa</i> reveals major cellular and extracellular proteins and a peculiar codon bias distribution. Proteomics, 2003, 3, 224-237.	2.2	87
204	Translational strategies to schizophrenia from a proteomic perspective. , 0, .		1
205	Proteome analysis of neural stem cells and neurospheres infected with Zika Virus. , 0, , .		0